US6258360B1
(en)
*
|
1989-05-04 |
2001-07-10 |
Igen International, Inc. |
Prodrugs activated by targeted catalytic proteins
|
US5527782A
(en)
*
|
1990-03-13 |
1996-06-18 |
Acic (Canada) Inc. |
5-halo-2,3'-O-cyclocytidines
|
AU671491B2
(en)
|
1992-12-18 |
1996-08-29 |
F. Hoffmann-La Roche Ag |
N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
|
TW254946B
(fr)
*
|
1992-12-18 |
1995-08-21 |
Hoffmann La Roche |
|
US5476932A
(en)
*
|
1994-08-26 |
1995-12-19 |
Hoffmann-La Roche Inc. |
Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
|
NZ330360A
(en)
*
|
1997-06-02 |
1999-03-29 |
Hoffmann La Roche |
5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
|
EP0882734B1
(fr)
*
|
1997-06-02 |
2009-08-26 |
F. Hoffmann-La Roche Ag |
Dérivés de 5'-déoxy-cytidine
|
US6005098A
(en)
*
|
1998-02-06 |
1999-12-21 |
Hoffmann-La Roche Inc. |
5'deoxycytidine derivatives
|
US20080113025A1
(en)
*
|
1998-11-02 |
2008-05-15 |
Elan Pharma International Limited |
Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
|
US20010051348A1
(en)
*
|
2000-01-28 |
2001-12-13 |
Lee Chee Wee |
Novel ligands and methods for preparing same
|
SE0102764D0
(sv)
|
2001-08-17 |
2001-08-17 |
Astrazeneca Ab |
Compounds
|
EP2266590A3
(fr)
|
2002-02-22 |
2011-04-20 |
Shire LLC |
Système d'administration de substances actives et méthodes de protection et d'administration de substances actives
|
US6774758B2
(en)
*
|
2002-09-11 |
2004-08-10 |
Kalyan P. Gokhale |
Low harmonic rectifier circuit
|
GB0226930D0
(en)
|
2002-11-19 |
2002-12-24 |
Astrazeneca Ab |
Chemical compounds
|
AU2003233586A1
(en)
*
|
2003-05-20 |
2005-01-21 |
Aronex Pharmaceuticals, Inc. |
Combination chemotherapy comprising capecitabine and a liposomal platinum complex
|
ATE402185T1
(de)
*
|
2003-12-22 |
2008-08-15 |
Hoffmann La Roche |
Verfahren für fluorcytidinderivate
|
CA2554686A1
(fr)
*
|
2004-02-18 |
2005-09-01 |
Astrazeneca Ab |
Composes
|
RU2392275C2
(ru)
*
|
2004-02-18 |
2010-06-20 |
Астразенека Аб |
Бензамидные производные и их применение в качестве активирующих глюкокиназу агентов
|
CN100383128C
(zh)
*
|
2004-02-23 |
2008-04-23 |
上海迪赛诺医药发展有限公司 |
N4-氧羰基胞嘧啶衍生物及制备方法与应用
|
TW200600086A
(en)
*
|
2004-06-05 |
2006-01-01 |
Astrazeneca Ab |
Chemical compound
|
KR101061850B1
(ko)
|
2004-09-08 |
2011-09-02 |
삼성전자주식회사 |
박막 트랜지스터 표시판 및 그 제조방법
|
GB0421294D0
(en)
*
|
2004-09-24 |
2004-10-27 |
Angiogene Pharm Ltd |
Bioreductively-activated prodrugs
|
GB0423043D0
(en)
*
|
2004-10-16 |
2004-11-17 |
Astrazeneca Ab |
Compounds
|
EP1802570A1
(fr)
|
2004-10-16 |
2007-07-04 |
AstraZeneca AB |
Procede de fabrication de composes de phenoxy benzamide
|
DE602006021142D1
(de)
|
2005-02-03 |
2011-05-19 |
Gen Hospital Corp |
Verfahren zur behandlung von gefitinib-resistentem krebs
|
NO322682B1
(no)
*
|
2005-03-18 |
2006-11-27 |
Clavis Pharma Asa |
Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
|
JP2008534548A
(ja)
*
|
2005-04-01 |
2008-08-28 |
エフ.ホフマン−ラ ロシュ アーゲー |
カペシタビンの投与のための方法
|
EP1891069A1
(fr)
*
|
2005-05-24 |
2008-02-27 |
AstraZeneca AB |
Derives d'imidazol[4,5b]pyridine/pyrazine et purine substitues en 2-phenyl en tant que modulateurs de la glucokinase
|
TW200714597A
(en)
|
2005-05-27 |
2007-04-16 |
Astrazeneca Ab |
Chemical compounds
|
US20080234273A1
(en)
*
|
2005-07-09 |
2008-09-25 |
Mckerrecher Darren |
Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
|
AU2006268406C1
(en)
|
2005-07-09 |
2011-02-24 |
Astrazeneca Ab |
Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
|
WO2007007040A1
(fr)
*
|
2005-07-09 |
2007-01-18 |
Astrazeneca Ab |
Composés 2-hétérocyclyloxybenzoyl amino hétérocyclyle en tant que modulateurs de glucokinase pour le traitement du diabète de type 2
|
CN100569790C
(zh)
*
|
2005-07-15 |
2009-12-16 |
上海奥锐特国际贸易有限公司 |
合成n4-酰基-5'-脱氧-5-氟胞苷衍生物的方法
|
CA2616008A1
(fr)
*
|
2005-07-21 |
2007-01-25 |
Stefan Meuer |
Solutions de chlorite stabilisees associees a des fluoropyrimidines pour traiter des cancers
|
US9202182B2
(en)
*
|
2005-08-11 |
2015-12-01 |
International Business Machines Corporation |
Method and system for analyzing business architecture
|
CN103110948A
(zh)
|
2005-11-04 |
2013-05-22 |
惠氏公司 |
mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
|
TW200738621A
(en)
|
2005-11-28 |
2007-10-16 |
Astrazeneca Ab |
Chemical process
|
US20080085310A1
(en)
*
|
2006-10-06 |
2008-04-10 |
Maria Oksana Bachynsky |
Capecitabine rapidly disintegrating tablets
|
TW200825063A
(en)
|
2006-10-23 |
2008-06-16 |
Astrazeneca Ab |
Chemical compounds
|
SA07280576B1
(ar)
|
2006-10-26 |
2011-06-22 |
استرازينيكا ايه بي |
مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
|
CN100425617C
(zh)
*
|
2006-10-31 |
2008-10-15 |
浙江海正药业股份有限公司 |
一种含氟嘧啶类化合物烷氧羰酰化的方法
|
EP2121666A1
(fr)
|
2006-12-21 |
2009-11-25 |
AstraZeneca AB |
Nouveau composé cristallin utile en tant qu'activateur de glk
|
ITMI20070435A1
(it)
|
2007-03-05 |
2008-09-06 |
Innovate Biotechnology Srl |
2',3'-di-o-acil-5-fluoronucleosidi
|
US20100130734A1
(en)
*
|
2007-04-20 |
2010-05-27 |
Dr. Reddy's Laboratories Ltd. |
Process for preparing capecitabine
|
EP2164856A1
(fr)
*
|
2007-06-01 |
2010-03-24 |
Synthon B.V. |
Procédés se rapportant à la fabrication de la capécitabine
|
WO2009042064A2
(fr)
|
2007-09-21 |
2009-04-02 |
Nektar Therapeutics Al, Corporation |
Conjugués nucléoside phosphate oligomères
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
US20090209754A1
(en)
*
|
2008-01-03 |
2009-08-20 |
Macdonald Peter Lindsay |
Process for the preparation of capecitabine
|
DK2656844T3
(en)
|
2008-06-17 |
2015-03-02 |
Wyeth Llc |
ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE
|
CN105963313A
(zh)
*
|
2008-08-04 |
2016-09-28 |
惠氏有限责任公司 |
4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
|
PE20110568A1
(es)
|
2008-08-04 |
2011-09-07 |
Astrazeneca Ab |
Agentes terapeuticos 414
|
WO2010065586A2
(fr)
*
|
2008-12-02 |
2010-06-10 |
Dr. Reddy's Laboratories Ltd. |
Préparation de capécitabine
|
US8603999B2
(en)
|
2008-12-05 |
2013-12-10 |
Commonwealth Scientific And Industrial Research Organisation |
Amphiphile prodrugs
|
CN101787066B
(zh)
*
|
2009-01-23 |
2013-07-31 |
高峰 |
阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
|
GB0902434D0
(en)
|
2009-02-13 |
2009-04-01 |
Astrazeneca Ab |
Chemical process
|
GB0902406D0
(en)
|
2009-02-13 |
2009-04-01 |
Astrazeneca Ab |
Crystalline polymorphic form
|
AU2010234968B2
(en)
|
2009-04-06 |
2015-05-14 |
Wyeth Llc |
Treatment regimen utilizing neratinib for breast cancer
|
AR076220A1
(es)
|
2009-04-09 |
2011-05-26 |
Astrazeneca Ab |
Derivados de pirazol [4,5 - e] pirimidina
|
AR076221A1
(es)
*
|
2009-04-09 |
2011-05-26 |
Astrazeneca Ab |
Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
|
CN101875680B
(zh)
*
|
2009-04-28 |
2012-07-25 |
上海信旗医药科技有限公司 |
一种核苷类化合物及其制备方法和应用
|
KR20120037932A
(ko)
*
|
2009-07-23 |
2012-04-20 |
시노팜 타이완 리미티드 |
플루오로시티딘 유도체를 제조하는 방법
|
SI2835053T1
(sl)
|
2010-03-12 |
2016-09-30 |
Genzyme Corporation |
Kombinirana terapija za zdravljenje raka dojke
|
AU2013243949A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
CA2868398A1
(fr)
|
2012-04-02 |
2013-10-10 |
Moderna Therapeutics, Inc. |
Polynucleotides modifies pour la production de proteines et de peptides cosmetiques
|
PL2900657T3
(pl)
|
2012-09-26 |
2020-07-27 |
F.Hoffmann-La Roche Ag |
Cykliczne związki eterowe pirazol-4-ilo-heterocyklilo-karboksyamidu i sposoby stosowania
|
US9447137B2
(en)
|
2012-11-07 |
2016-09-20 |
Nucorion Pharmaceuticals, Inc. |
Substituted gemcitabine aryl amide analogs
|
US10000521B2
(en)
|
2013-03-15 |
2018-06-19 |
Nucorion Pharmaceuticals, Inc. |
Substituted gemcitabine bicyclic amide analogs and treatment methods using same
|
US10138507B2
(en)
|
2013-03-15 |
2018-11-27 |
Modernatx, Inc. |
Manufacturing methods for production of RNA transcripts
|
WO2015034928A1
(fr)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Polynucléotides chimériques
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
CN103450301B
(zh)
*
|
2013-09-09 |
2015-09-09 |
南通大学 |
法尼基硫代水杨酸-核苷缀合物、其制备方法及其医药用途
|
JP2016538829A
(ja)
|
2013-10-03 |
2016-12-15 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
低密度リポタンパク質受容体をコードするポリヌクレオチド
|
KR102306412B1
(ko)
*
|
2016-06-28 |
2021-09-28 |
셀릭스 바이오 프라이빗 리미티드 |
암 치료용 조성물 및 방법
|
EP3565549B1
(fr)
|
2017-01-09 |
2022-03-09 |
Shuttle Pharmaceuticals, Inc. |
Inhibiteurs sélectifs d'histone déacétylase pour le traitement d'une maladie humaine
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
CA3061621A1
(fr)
|
2017-04-26 |
2018-11-01 |
Thomas I. Kalman |
Derives de nucleoside multicibles
|
US10435429B2
(en)
|
2017-10-03 |
2019-10-08 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouridine monophosphate cyclic triester compounds
|
EP3737376B1
(fr)
|
2018-01-09 |
2024-04-17 |
Shuttle Pharmaceuticals, Inc. |
Inhibiteurs sélectifs d'histone déacétylase pour le traitement de maladies humaines
|
WO2019143860A1
(fr)
*
|
2018-01-19 |
2019-07-25 |
Nucorion Pharmaceuticals, Inc. |
Composés de 5-fluorouracile
|
US11427550B2
(en)
|
2018-01-19 |
2022-08-30 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouracil compounds
|
JP2021534085A
(ja)
*
|
2018-08-03 |
2021-12-09 |
セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited |
癌治療のための組成物及び方法
|
CN109651467A
(zh)
*
|
2019-01-15 |
2019-04-19 |
齐鲁天和惠世制药有限公司 |
一种卡培他滨杂质及其制备方法
|
JP2023523415A
(ja)
|
2020-04-21 |
2023-06-05 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
ヌクレオチドプロドラッグ化合物
|
CN116710079A
(zh)
|
2020-07-24 |
2023-09-05 |
斯特兰德生物科技公司 |
包含经修饰的核苷酸的脂质纳米颗粒
|
JP2024503000A
(ja)
|
2021-01-08 |
2024-01-24 |
ストランド セラピューティクス インコーポレイテッド |
発現構築物およびその使用
|
WO2023212618A1
(fr)
|
2022-04-26 |
2023-11-02 |
Strand Therapeutics Inc. |
Nanoparticules lipidiques comprenant un réplicon d'encéphalite équine du vénézuela (vee) et leurs utilisations
|